Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer

NCT06111781 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT06111781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06111781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Recruiting
Start date
April 15, 2024
Completion date
February 29, 2028
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer